Topical Metformin: A Review of Clinical Evidence and Compounding Considerations
by Zachary T. Ladwig, PharmD Candidate 2027
Abstract:
Background: Metformin is widely used for type 2 diabetes mellitus, but emerging evidence highlights its anti-inflammatory, antifibrotic, and wound-modulating effects via activation of AMP-activated protein kinase (AMPK). These properties have spurred interest in topical metformin for dermatologic and tissue-healing applications, despite the lack of FDA-approved formulations. This literature review evaluates the safety, efficacy, and compounding considerations of compounded topical metformin, providing rationale and proposed mechanisms for topical use while summarizing preclinical and clinical evidence.
Methods: A comprehensive search of PubMed, EBSCO, Medline, and International Pharmaceutical Abstracts identified English-language studies (January 1, 2019-October 1, 2025) involving topical or locally applied metformin in human or animal models. Exclusions included oral-only metformin studies and systematic reviews. Additional guidance was gathered from United States Pharmacopeia <795> standards, Centers for Disease Control and Prevention or Food and Drug Administration publications, Trissel’s Stability of Compounded Formulations, and the International Journal of Pharmaceutical Compounding.
Results: Across 12 studies, topical metformin (concentrations 0.5% to 30%) consistently improved inflammation, pigmentation, scar characteristics, periodontal outcomes, and hair growth, with minimal adverse effects. Evidence is strongest for chronic periodontitis and melasma, with promising early findings in wound healing and central centrifugal cicatricial alopecia. Limitations include small sample sizes, heterogeneous formulations, and lack of pharmacokinetic data.
Conclusion: Topical metformin is a mechanistically rational compounded therapy showing promising therapeutic potential with broad dermatologic applicability. It appears well tolerated and can produce clinically meaningful improvements. Standardized formulations tested in large, multicenter randomized controlled trials are needed to support broad clinical adoption.
Download PDF
2026 September/October Table of Contents
Abstract:
Background: Metformin is widely used for type 2 diabetes mellitus, but emerging evidence highlights its anti-inflammatory, antifibrotic, and wound-modulating effects via activation of AMP-activated protein kinase (AMPK). These properties have spurred interest in topical metformin for dermatologic and tissue-healing applications, despite the lack of FDA-approved formulations. This literature review evaluates the safety, efficacy, and compounding considerations of compounded topical metformin, providing rationale and proposed mechanisms for topical use while summarizing preclinical and clinical evidence.
Methods: A comprehensive search of PubMed, EBSCO, Medline, and International Pharmaceutical Abstracts identified English-language studies (January 1, 2019-October 1, 2025) involving topical or locally applied metformin in human or animal models. Exclusions included oral-only metformin studies and systematic reviews. Additional guidance was gathered from United States Pharmacopeia <795> standards, Centers for Disease Control and Prevention or Food and Drug Administration publications, Trissel’s Stability of Compounded Formulations, and the International Journal of Pharmaceutical Compounding.
Results: Across 12 studies, topical metformin (concentrations 0.5% to 30%) consistently improved inflammation, pigmentation, scar characteristics, periodontal outcomes, and hair growth, with minimal adverse effects. Evidence is strongest for chronic periodontitis and melasma, with promising early findings in wound healing and central centrifugal cicatricial alopecia. Limitations include small sample sizes, heterogeneous formulations, and lack of pharmacokinetic data.
Conclusion: Topical metformin is a mechanistically rational compounded therapy showing promising therapeutic potential with broad dermatologic applicability. It appears well tolerated and can produce clinically meaningful improvements. Standardized formulations tested in large, multicenter randomized controlled trials are needed to support broad clinical adoption.
Download PDF
2026 September/October Table of Contents